2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke

to related objects

Location: Deutsche Nationalbibliothek Frankfurt am Main

ISSN: 1619-7089

Extent: Online-Ressource

Language: Englisch

Notes: online resource.

Bibliographic citation: 2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? ; volume:48 ; number:9 ; day:22 ; month:5 ; year:2021 ; pages:2668-2669 ; date:8.2021
European journal of nuclear medicine and molecular imaging ; 48, Heft 9 (22.5.2021), 2668-2669, 8.2021

Creator: Herrmann, Ken
Kratochwil, Clemens
Fendler, Wolfgang P.
Eiber, Matthias
Hustinx, Roland

Contributor: SpringerLink (Online service)

DOI: 10.1007/s00259-021-05409-w

URN: urn:nbn:de:101:1-2021101601312613143288

Rights: Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.

Last update: 15.08.2025, 7:27 AM CEST

Data provider

This object is provided by:
Deutsche Nationalbibliothek. If you have any questions about the object, please contact the data provider.

Show original at data provider

Associated

Herrmann, Ken
Kratochwil, Clemens
Fendler, Wolfgang P.
Eiber, Matthias
Hustinx, Roland
SpringerLink (Online service)

Other Objects (12)

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu‐PSMA therapy

Structural modifications of PSMA ligands to optimize their pharmacokinetics

Die ⁶⁸Gallium-PSMA-PET/MRT in der Primärdetektion des Prostatakarzinoms

Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]

Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu‐PSMA therapy

Structural modifications of PSMA ligands to optimize their pharmacokinetics

Die ⁶⁸Gallium-PSMA-PET/MRT in der Primärdetektion des Prostatakarzinoms

Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]

Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu‐PSMA therapy

Structural modifications of PSMA ligands to optimize their pharmacokinetics

Die ⁶⁸Gallium-PSMA-PET/MRT in der Primärdetektion des Prostatakarzinoms

Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]

Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure

Cultural heritage institutions wishing to register will find more information here.

Fields marked * need to be filled in.

Username*

Please enter your username

Email*

Please enter your email address

Please do not fill this field

First name

Last name

Password*

Please enter your password

Confirm password*

Please enter the same password

I have read the terms of use and the privacy policy for the collection of personal data and accept them. *

This field is required.

I would like to subscribe to the newsletter of the Deutsche Digitale Bibliothek. See newsletter subscription info.

Account created

Your "My DDB" account has been successfully created. Before you can log in to your account, you must click the confirmation link in the message we just sent to the email address you provided.

2021: the year [177Lu]Lu-PSMA-617 RLT PSMA is ready for incorporation into clinical guidelines? : Reply to “A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands” by Dr. Germo Gericke

Object Details

References and Relationships

Contributors, Places and Time

Further information

Data provider

Associated

Other Objects (12)

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu‐PSMA therapy

Structural modifications of PSMA ligands to optimize their pharmacokinetics

Die ⁶⁸Gallium-PSMA-PET/MRT in der Primärdetektion des Prostatakarzinoms

Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]

Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu‐PSMA therapy

Structural modifications of PSMA ligands to optimize their pharmacokinetics

Die ⁶⁸Gallium-PSMA-PET/MRT in der Primärdetektion des Prostatakarzinoms

Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]

Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure

Influence of sampling schedules on [177Lu]Lu-PSMA dosimetry

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Joint EANM/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)

Preclinical comparison of [177Lu]Lu-rhPSMA-10.1 and [177Lu]Lu-rhPSMA-10.2 for endoradiotherapy of prostate cancer: biodistribution and dosimetry studies

Long-term nephrotoxicity of 177Lu-PSMA radioligand therapy

A perspective on the EANM procedure guidelines for radionuclide therapy with 177Lu-labelled PSMA-ligands

E-PSMA: the EANM standardized reporting guidelines v1.0 for PSMA-PET

Technical Note: Optimal sampling schedules for kidney dosimetry based on the hybrid planar/SPECT method in 177Lu‐PSMA therapy

Structural modifications of PSMA ligands to optimize their pharmacokinetics

Die ⁶⁸Gallium-PSMA-PET/MRT in der Primärdetektion des Prostatakarzinoms

Improved therapeutic index with the novel PSMA-ligand 177Lu-rhPSMA-10.1 compared to 177Lu-PSMA I&T - an intrapatient comparison [Abstract]

Dual Radionuclide Therapy: The Synergistic Effects of [161Tb]Tb-PSMA and [177Lu]Lu-PSMA in Advanced Prostate Cancer Post [177Lu]Lu-PSMA Failure

Related objects

Reset password